{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:14Z","timestamp":1790668514136,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01259-2","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:11:39Z","timestamp":1785258699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An In Vitro Quantitative Systems Pharmacology Platform for Characterizing CD3-Bispecific Antibody-Mediated T-Cell Activation and Tumor Cell Cytotoxicity"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3510-691X","authenticated-orcid":false,"given":"Xuanzhen","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8500-8277","authenticated-orcid":false,"given":"Craig","family":"Thalhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4354-9997","authenticated-orcid":false,"given":"Nasrin","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-6902","authenticated-orcid":false,"given":"Kristel","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-7663","authenticated-orcid":false,"given":"Guohua","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-9436","authenticated-orcid":false,"given":"Tommy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"1259_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/1547691X.2020.1729902","volume":"17","author":"C Kamperschroer","year":"2020","unstructured":"Kamperschroer C, Shenton J, Lebrec H, Leighton JK, Moore PA, Thomas O. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. J Immunotoxicol. 2020;17(1):67\u201385. https:\/\/doi.org\/10.1080\/1547691X.2020.1729902.","journal-title":"J Immunotoxicol."},{"key":"1259_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","volume":"182","author":"Z Wu","year":"2018","unstructured":"Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacol Ther. 2018;182:161\u201375. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.005.","journal-title":"Pharmacol Ther."},{"key":"1259_CR3","doi-asserted-by":"publisher","unstructured":"Kemper K, Gielen E, Boross P, Houtkamp M, Plantinga TS, de Poot SA, et al. Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life Sci Alliance. 2022;5(11):e202201481. https:\/\/doi.org\/10.26508\/lsa.202201481.","DOI":"10.26508\/lsa.202201481"},{"issue":"18","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0612.","journal-title":"Clin Cancer Res."},{"issue":"16","key":"1259_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Teclistamab: first approval. Drugs. 2022;82(16):1613\u20139. https:\/\/doi.org\/10.1007\/s40265-022-01793-1.","journal-title":"Drugs."},{"issue":"10","key":"1259_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10(10):893\u2013919. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.002.","journal-title":"Trends Cancer."},{"issue":"5","key":"1259_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-025-02163-3","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam SJ. Zanidatamab: first approval. Drugs. 2025;85(5):707\u201314. https:\/\/doi.org\/10.1007\/s40265-025-02163-3.","journal-title":"Drugs."},{"key":"1259_CR8","doi-asserted-by":"publisher","first-page":"1020003","DOI":"10.3389\/fimmu.2022.1020003","volume":"13","author":"J Kang","year":"2022","unstructured":"Kang J, Sun T, Zhang Y. Immunotherapeutic progress and application of bispecific antibody in cancer. Front Immunol. 2022;13:1020003. https:\/\/doi.org\/10.3389\/fimmu.2022.1020003.","journal-title":"Front Immunol."},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fonc.2020.00446","volume":"10","author":"O Vafa","year":"2020","unstructured":"Vafa O, Trinklein ND. Perspective: designing T-cell engagers with better therapeutic windows. Front Oncol. 2020;10:446. https:\/\/doi.org\/10.3389\/fonc.2020.00446.","journal-title":"Front Oncol."},{"key":"1259_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625.","journal-title":"EBioMedicine."},{"issue":"19","key":"1259_CR11","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0455.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"1259_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cpt.3302","volume":"116","author":"X Liao","year":"2024","unstructured":"Liao X, Qi T, Zhou J, Liu C, Cao Y. Optimizing clinical translation of bispecific T-cell engagers through context unification with a quantitative systems pharmacology model. Clin Pharmacol Ther. 2024;116(2):415\u201325. https:\/\/doi.org\/10.1002\/cpt.3302.","journal-title":"Clin Pharmacol Ther."},{"key":"1259_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","volume":"90","author":"H Saber","year":"2017","unstructured":"Saber H, Del Valle P, Ricks TK, Leighton JK. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol. 2017;90:144\u201352. https:\/\/doi.org\/10.1016\/j.yrtph.2017.09.001.","journal-title":"Regul Toxicol Pharmacol."},{"issue":"1","key":"1259_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1208\/s12248-021-00637-2","volume":"24","author":"A Van De Vyver","year":"2021","unstructured":"Van De Vyver A, Eigenmann M, Ovacik M, Pohl C, Herter S, Weinzierl T, et al. A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in vitro time course experiments and streamlined data analysis. AAPS J. 2021;24(1):7. https:\/\/doi.org\/10.1208\/s12248-021-00637-2.","journal-title":"AAPS J."},{"issue":"10","key":"1259_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205491","volume":"13","author":"J Harper","year":"2018","unstructured":"Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, et al. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS One. 2018;13(10):e0205491. https:\/\/doi.org\/10.1371\/journal.pone.0205491.","journal-title":"PLoS One."},{"key":"1259_CR16","doi-asserted-by":"publisher","unstructured":"Register AC, Tarighat SS, Lee HY. Bioassay development for bispecific antibodies-challenges and opportunities. Int J Mol Sci. 2021;22(10):5350. https:\/\/doi.org\/10.3390\/ijms22105350.","DOI":"10.3390\/ijms22105350"},{"issue":"12","key":"1259_CR17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.tips.2023.09.009","volume":"44","author":"T Qi","year":"2023","unstructured":"Qi T, Liao X, Cao Y. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends Pharmacol Sci. 2023;44(12):880\u201390. https:\/\/doi.org\/10.1016\/j.tips.2023.09.009.","journal-title":"Trends Pharmacol Sci."},{"issue":"2","key":"1259_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-20-0269","volume":"20","author":"AJ Van De Vyver","year":"2021","unstructured":"Van De Vyver AJ, Weinzierl T, Eigenmann MJ, Frances N, Herter S, Buser RB, et al. Predicting tumor killing and t-cell activation by T-cell bispecific antibodies as a function of target expression: combining in vitro experiments with systems modeling. Mol Cancer Ther. 2021;20(2):357\u201366. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0269.","journal-title":"Mol Cancer Ther."},{"issue":"6","key":"1259_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/19420862.2018.1480299","volume":"10","author":"X Jiang","year":"2018","unstructured":"Jiang X, Chen X, Carpenter TJ, Wang J, Zhou R, Davis HM, et al. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs. 2018;10(6):876\u201389. https:\/\/doi.org\/10.1080\/19420862.2018.1480299.","journal-title":"MAbs"},{"issue":"6","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/a:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332. https:\/\/doi.org\/10.1023\/a:1014414520282.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"16","key":"1259_CR21","doi-asserted-by":"publisher","first-page":"6799","DOI":"10.1074\/jbc.M116.763888","volume":"292","author":"K Li","year":"2017","unstructured":"Li K, Cheng X, Tilevik A, Davis SJ, Zhu C. In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem. 2017;292(16):6799\u2013809. https:\/\/doi.org\/10.1074\/jbc.M116.763888.","journal-title":"J Biol Chem."},{"issue":"3","key":"1259_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0006-3495(98)74074-3","volume":"75","author":"SE Chesla","year":"1998","unstructured":"Chesla SE, Selvaraj P, Zhu C. Measuring two-dimensional receptor-ligand binding kinetics by micropipette. Biophys J. 1998;75(3):1553\u201372. https:\/\/doi.org\/10.1016\/S0006-3495(98)74074-3.","journal-title":"Biophys J."},{"issue":"4","key":"1259_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1615\/CritRevImmunol.v20.i4.20","volume":"20","author":"A Alcover","year":"2000","unstructured":"Alcover A, Alarcon B. Internalization and intracellular fate of TCR-CD3 complexes. Crit Rev Immunol. 2000;20(4):325\u201346. https:\/\/doi.org\/10.1615\/CritRevImmunol.v20.i4.20.","journal-title":"Crit Rev Immunol."},{"issue":"1","key":"1259_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","volume":"37","author":"C Chalouni","year":"2018","unstructured":"Chalouni C, Doll S. Fate of Antibody-Drug Conjugates in Cancer Cells. J Exp Clin Cancer Res. 2018;37(1):20. https:\/\/doi.org\/10.1186\/s13046-017-0667-1.","journal-title":"J Exp Clin Cancer Res."},{"issue":"15","key":"1259_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217562120","volume":"120","author":"N Sato","year":"2023","unstructured":"Sato N, Bamford RN, Bryant BR, Tagaya Y, Waldmann TA. Accessory cells precondition naive T cells and regulatory T cells for cytokine-mediated proliferation. Proc Natl Acad Sci U S A. 2023;120(15):e2217562120. https:\/\/doi.org\/10.1073\/pnas.2217562120.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1259_CR26","volume-title":"Enzyme kinetics for systems biology","author":"HM Sauro","year":"2012","unstructured":"Sauro HM. Enzyme kinetics for systems biology. 2nd ed. Ambrosius Publishing; 2012.","edition":"2"},{"issue":"39","key":"1259_CR27","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.1021\/bi201284u","volume":"50","author":"KA Johnson","year":"2011","unstructured":"Johnson KA, Goody RS. The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. Biochemistry. 2011;50(39):8264\u20139. https:\/\/doi.org\/10.1021\/bi201284u.","journal-title":"Biochemistry."},{"issue":"4","key":"1259_CR28","doi-asserted-by":"publisher","first-page":"F9","DOI":"10.1084\/jem.192.4.f9","volume":"192","author":"CD Surh","year":"2000","unstructured":"Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med. 2000;192(4):F9\u2013F14. https:\/\/doi.org\/10.1084\/jem.192.4.f9.","journal-title":"J Exp Med."},{"issue":"3","key":"1259_CR29","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.4049\/jimmunol.175.3.1575","volume":"175","author":"A Jansson","year":"2005","unstructured":"Jansson A, Barnes E, Klenerman P, Harlen M, Sorensen P, Davis SJ, et al. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol. 2005;175(3):1575\u201385. https:\/\/doi.org\/10.4049\/jimmunol.175.3.1575.","journal-title":"J Immunol."},{"issue":"6","key":"1259_CR30","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/eji.200425857","volume":"35","author":"C Brossard","year":"2005","unstructured":"Brossard C, Feuillet V, Schmitt A, Randriamampita C, Romao M, Raposo G, et al. Multifocal structure of the T cell - dendritic cell synapse. Eur J Immunol. 2005;35(6):1741\u201353. https:\/\/doi.org\/10.1002\/eji.200425857.","journal-title":"Eur J Immunol."},{"issue":"22","key":"1259_CR31","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1091\/mbc.E16-06-0414","volume":"27","author":"L Guillou","year":"2016","unstructured":"Guillou L, Babataheri A, Saitakis M, Bohineust A, Dogniaux S, Hivroz C, et al. T-lymphocyte passive deformation is controlled by unfolding of membrane surface reservoirs. Mol Biol Cell. 2016;27(22):3574\u201382. https:\/\/doi.org\/10.1091\/mbc.E16-06-0414.","journal-title":"Mol Biol Cell."},{"issue":"4","key":"1259_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cell.2015.03.031","volume":"161","author":"EM Steinert","year":"2015","unstructured":"Steinert EM, Schenkel JM, Fraser KA, Beura LK, Manlove LS, Igyarto BZ, et al. Quantifying memory CD8 T cells reveals regionalization of immunosurveillance. Cell. 2015;161(4):737\u201349. https:\/\/doi.org\/10.1016\/j.cell.2015.03.031.","journal-title":"Cell."},{"issue":"10","key":"1259_CR33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-13-0108","volume":"12","author":"H Song","year":"2013","unstructured":"Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, et al. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. 2013;12(10):2043\u201354. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0108.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1259_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4049\/jimmunol.173.1.384","volume":"173","author":"M von Essen","year":"2004","unstructured":"von Essen M, Bonefeld CM, Siersma V, Rasmussen AB, Lauritsen JP, Nielsen BL, et al. Constitutive and ligand-induced TCR degradation. J Immunol. 2004;173(1):384\u201393. https:\/\/doi.org\/10.4049\/jimmunol.173.1.384.","journal-title":"J Immunol"},{"issue":"2","key":"1259_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cyto.b.20496","volume":"78","author":"FZ El Hentati","year":"2010","unstructured":"El Hentati FZ, Gruy F, Iobagiu C, Lambert C. Variability of CD3 membrane expression and T cell activation capacity. Cytometry B Clin Cytom. 2010;78(2):105\u201314. https:\/\/doi.org\/10.1002\/cyto.b.20496.","journal-title":"Cytometry B Clin Cytom."},{"issue":"5","key":"1259_CR36","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cpt.2729","volume":"112","author":"T Li","year":"2022","unstructured":"Li T, Hiemstra IH, Chiu C, Oliveri RS, Elliott B, DeMarco D, et al. Semimechanistic physiologically-based pharmacokinetic\/pharmacodynamic model informing epcoritamab dose selection for patients with B-cell lymphomas. Clin Pharmacol Ther. 2022;112(5):1108\u201319. https:\/\/doi.org\/10.1002\/cpt.2729.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"1259_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/1535-7163.MCT-13-0324","volume":"13","author":"RB Slee","year":"2014","unstructured":"Slee RB, Grimes BR, Bansal R, Gore J, Blackburn C, Brown L, et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther. 2014;13(2):307\u201315. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0324.","journal-title":"Mol Cancer Ther."},{"issue":"49","key":"1259_CR38","doi-asserted-by":"publisher","first-page":"86369","DOI":"10.18632\/oncotarget.21174","volume":"8","author":"NN Kalu","year":"2017","unstructured":"Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, et al. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget. 2017;8(49):86369\u201383. https:\/\/doi.org\/10.18632\/oncotarget.21174.","journal-title":"Oncotarget."},{"key":"1259_CR39","doi-asserted-by":"publisher","unstructured":"Cunningham D, You Z. In vitro and in vivo model systems used in prostate cancer research. J Biol Methods. 2015;2(1). https:\/\/doi.org\/10.14440\/jbm.2015.63.","DOI":"10.14440\/jbm.2015.63"},{"key":"1259_CR40","unstructured":"German Collection of Microorganisms and Cell Cultures (DSMZ). EPLC-272H (ACC-383) Cell Line Datasheet. Available from: https:\/\/www.dsmz.de\/collection\/catalogue\/details\/culture\/ACC-383."},{"key":"1259_CR41","doi-asserted-by":"publisher","unstructured":"Diehl S, Hildebrandt G, Manda K. Pepper alkaloid piperine increases radiation sensitivity of cancer cells from glioblastoma and hypopharynx in vitro. Int J Mol Sci. 2022;23(15) https:\/\/doi.org\/10.3390\/ijms23158548.","DOI":"10.3390\/ijms23158548"},{"issue":"9","key":"1259_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203040","volume":"13","author":"V Biswenger","year":"2018","unstructured":"Biswenger V, Baumann N, Jurschick J, Hackl M, Battle C, Schwarz J, et al. Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly sensitive assay system. PLoS One. 2018;13(9):e0203040. https:\/\/doi.org\/10.1371\/journal.pone.0203040.","journal-title":"PLoS One."},{"issue":"1","key":"1259_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13058-020-01300-y","volume":"22","author":"J Finlay-Schultz","year":"2020","unstructured":"Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020;22(1):68. https:\/\/doi.org\/10.1186\/s13058-020-01300-y.","journal-title":"Breast Cancer Res."},{"issue":"1","key":"1259_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/or.2014.3599","volume":"33","author":"C Wang","year":"2015","unstructured":"Wang C, Zhang W, Fu M, Yang A, Huang H, Xie J. Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression. Oncol Rep. 2015;33(1):383\u201390. https:\/\/doi.org\/10.3892\/or.2014.3599.","journal-title":"Oncol Rep."},{"issue":"5","key":"1259_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3892\/ol.2020.12093","volume":"20","author":"J Liu","year":"2020","unstructured":"Liu J, Huang Y, Zhu D, Dai Y, Liu D, Zhai Y, et al. Establishment and characterization of a docetaxel-resistant human prostate cancer cell line. Oncol Lett. 2020;20(5):230. https:\/\/doi.org\/10.3892\/ol.2020.12093.","journal-title":"Oncol Lett."},{"issue":"1","key":"1259_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13104-016-2256-3","volume":"9","author":"S Vallo","year":"2016","unstructured":"Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, et al. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016;9(1):454. https:\/\/doi.org\/10.1186\/s13104-016-2256-3.","journal-title":"BMC Res Notes."},{"key":"1259_CR47","doi-asserted-by":"publisher","unstructured":"Coon J, Kingsley K. Assessment of microRNA (miR)-365 effects on oral squamous carcinoma cell line phenotypes. Biomolecules. 2021;11(6):874. https:\/\/doi.org\/10.3390\/biom11060874.","DOI":"10.3390\/biom11060874"},{"issue":"1","key":"1259_CR48","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41598-018-38315-7","volume":"9","author":"MN Rosa","year":"2019","unstructured":"Rosa MN, Evangelista AF, Leal LF, De Oliveira CM, Silva VAO, Munari CC, et al. Establishment, molecular and biological characterization of HCB-514: a novel human cervical cancer cell line. Sci Rep. 2019;9(1):1913. https:\/\/doi.org\/10.1038\/s41598-018-38315-7.","journal-title":"Sci Rep."},{"issue":"1","key":"1259_CR49","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41598-022-07228-x","volume":"12","author":"M Davern","year":"2022","unstructured":"Davern M, M O'B, McGrath J, Donlon NE, Melo AM, Buckley CE, et al. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma. Sci Rep. 2022;12(1):3259. https:\/\/doi.org\/10.1038\/s41598-022-07228-x.","journal-title":"Sci Rep."},{"issue":"9","key":"1259_CR50","first-page":"3997","volume":"44","author":"AA Kyriazis","year":"1984","unstructured":"Kyriazis AA, Kyriazis AP, McCombs WB 3rd, Peterson WD Jr. Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice. Cancer Res. 1984;44(9):3997\u20134005.","journal-title":"Cancer Res."},{"issue":"1","key":"1259_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98\u2013104. https:\/\/doi.org\/10.1002\/ijc.20908.","journal-title":"Int J Cancer."},{"issue":"3","key":"1259_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","volume":"108","author":"A Betts","year":"2020","unstructured":"Betts A, van der Graaf PH. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther. 2020;108(3):528\u201341. https:\/\/doi.org\/10.1002\/cpt.1961.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"1259_CR53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383\u201395. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.001.","journal-title":"Cancer Cell."},{"key":"1259_CR54","doi-asserted-by":"publisher","unstructured":"Liu C, Zhou J, Kudlacek S, Qi T, Dunlap T, Cao Y. Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. Elife. 2023:12. https:\/\/doi.org\/10.7554\/eLife.83659.","DOI":"10.7554\/eLife.83659"},{"issue":"8","key":"1259_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00262-025-04036-w","volume":"74","author":"R Nakamura","year":"2025","unstructured":"Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M. Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity. Cancer Immunol Immunother. 2025;74(8):246. https:\/\/doi.org\/10.1007\/s00262-025-04036-w.","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"1259_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2326-6066.CIR-20-0080","volume":"9","author":"SQ Liu","year":"2021","unstructured":"Liu SQ, Grantham A, Landry C, Granda B, Chopra R, Chakravarthy S, et al. A CRISPR screen reveals resistance mechanisms to CD3-bispecific antibody therapy. Cancer Immunol Res. 2021;9(1):34\u201349. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0080.","journal-title":"Cancer Immunol Res."},{"issue":"1","key":"1259_CR57","doi-asserted-by":"publisher","first-page":"20068","DOI":"10.1038\/s41598-019-56670-x","volume":"9","author":"CE Decker","year":"2019","unstructured":"Decker CE, Young T, Pasnikowski E, Chiu J, Song H, Wei Y, et al. Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy. Sci Rep. 2019;9(1):20068. https:\/\/doi.org\/10.1038\/s41598-019-56670-x.","journal-title":"Sci Rep."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01259-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01259-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01259-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:29Z","timestamp":1790665349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01259-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01259-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT, NA, KK, TL are employees of Genmab and may own stock or stock options.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tool: Xuanzhen Yuan wrote the original draft of the manuscript and used ChatGPT for grammar checking and language polishing.\u00a0References: All parameter values sourced from the literatures were carefully reviewed, and each cited reference was verified to support the corresponding content in the manuscript, including parameter values, background statements and methodological context.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"123"}}